Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.
Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments, plus royalties on net sales.
Peter van de Sande, Chief Executive Officer of Synaffix, said: “By combining our cutting-edge ADC technology platform with Hummingbird Bio’s next-generation portfolio of precision therapeutics we can further contribute towards the transformation of cancer treatment.”
For the target licensed, Hummingbird Bio is granted rights to utilise Synaffix ADC technologies GlycoConnect and HydraSpace, in combination with select toxSYN linker-payloads.
“We believe that, by combining Synaffix’s ADC technologies with our antibodies, we have the potential to create best-in-class ADCs,” said Piers Ingram, Chief Executive Officer and co-founder of Hummingbird Bio.
